**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Burande, Aksha1, Fine, Nowell2, Miller, Robert2, Hahn, Christopher, Mahe4, Ettiene1, Bosley, Debra2, Litwin, Lyndsay2 and Jimenez-Zepeda,Victor1,3

**Main Body of the Abstract**
Background: The diagnosis and management of amyloidosis requires coordination between multiple specialists to facilitate the diagnostic pathway for suspected cases. Objectives We reviewed the referral patterns to the cardiac and hematology amyloid clinics since the inception of the Amyloidosis Program of Calgary (APC) in 2019. Methods The APC is a multidisciplinary program that aims to facilitate the diagnosis and treatment of amyloidosis. A central referral system was created to expedite the evaluation of cases with potential amyloid related symptoms.  Results The Cardiac Amyloidosis Clinic received 41 referrals in 2018 and the number of referrals increased up to 105 in 2022. During 2020 (COVID-19 pandemic), the number of referrals decreased from 67 in 2019 to 56 (Figure 1a). Most referrals came from general cardiology clinics, followed by hematology. 50% of the cases referred were ultimately diagnosed with ATTR and 18% with AL amyloidosis. The Amyloidosis Clinic at our Cancer Center was created in 2019. The number of AL amyloidosis cases remained stable with an increase from 16 to 25 new cases from 2018 to 2023 (Figure 1b) Conclusion: We report here the impact of the formation of a dedicated multidisciplinary amyloidosis program in Calgary and the patterns of referrals from other services since its creation. An increase of ATTR referrals has been noted since the inception of the program, whereas the AL amyloidosis patients remain constant. The diagnosis of non-AL/ATTR cases have also increased as result of a more consistent typing protocol.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Burande, Aksha_1_, Fine, Nowell2, Miller, Robert2, Hahn, Christopher, Mahe4, Ettiene_1_, Bosley, Debra2, Litwin, Lyndsay2 and Jimenez-Zepeda,Victor1,3

**Main Body of the Abstract**
**Background**: The diagnosis and management of amyloidosis requires coordination between multiple specialists to facilitate the diagnostic pathway for suspected cases. **Objectives** We reviewed the referral patterns to the cardiac and hematology amyloid clinics since the inception of the Amyloidosis Program of Calgary (APC) in 2019. **Methods** The APC is a multidisciplinary program that aims to facilitate the diagnosis and treatment of amyloidosis. A central referral system was created to expedite the evaluation of cases with potential amyloid related symptoms.  **Results** The Cardiac Amyloidosis Clinic received 41 referrals in 2018 and the number of referrals increased up to 105 in 2022. During 2020 (COVID-19 pandemic), the number of referrals decreased from 67 in 2019 to 56 (**Figure 1a**). Most referrals came from general cardiology clinics, followed by hematology. 50% of the cases referred were ultimately diagnosed with ATTR and 18% with AL amyloidosis. The Amyloidosis Clinic at our Cancer Center was created in 2019. The number of AL amyloidosis cases remained stable with an increase from 16 to 25 new cases from 2018 to 2023 (**Figure 1b**) **Conclusion**: We report here the impact of the formation of a dedicated multidisciplinary amyloidosis program in Calgary and the patterns of referrals from other services since its creation. An increase of ATTR referrals has been noted since the inception of the program, whereas the AL amyloidosis patients remain constant. The diagnosis of non-AL/ATTR cases have also increased as result of a more consistent typing protocol.



Referral patterns in AL and ATTR Amyloidosis: Initial experience from the Amyloidosis Program of Calgary: Role of a Multidisciplanary approach PA64 (#309)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.